{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-016319","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2023-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.018647+00:00","generated_at":"2026-06-14T09:17:37.806103+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Atossa appoints Greg Weaver as CFO, succeeding Kyle Guse effective June 1, 2023","bullets":["Greg Weaver appointed EVP and CFO effective June 1, 2023, succeeding Kyle Guse who ceased as of May 26, 2023.","Weaver receives $450K base salary, 45% target bonus, $125K sign-on, and 2.6M stock options vesting over 4 years.","Weaver previously served as CFO of BioIntelliSense, Atai Life Sciences, and Eloxx Pharmaceuticals; also a director since 2013.","Guse will receive severance benefits per his employment agreement upon termination without cause.","Weaver's severance includes 6 months salary/benefits, or 12 months with equity acceleration upon change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-016319","json":"https://secwatch.observer/filing/0001437749-23-016319.json","markdown":"https://secwatch.observer/filing/0001437749-23-016319.md","text":"https://secwatch.observer/filing/0001437749-23-016319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/0001437749-23-016319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/atos20230526_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T09:17:37.806103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b5ffb307b","claim":"Kyle Guse departed as General Counsel and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..","evidence_excerpt":"Mr. Weaver succeeds Kyle Guse, who ceased to serve as the Company’s General Counsel and Chief Financial Officer as of May 26, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/0001437749-23-016319-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to serve"},{"label":"Role","value":"General Counsel and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a855ad4d35","claim":"Greg Weaver was appointed as Executive Vice President and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..","evidence_excerpt":"Effective as of June 1, 2023 (the “Effective Date”), Atossa Therapeutics, Inc. (the “Company”) appointed Greg Weaver as the Company’s Executive Vice President and Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/0001437749-23-016319-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}